ubiquitin specific protease 3 fragment
(Synonyms: H2N-Ser-Thr-Thr-Ala-Ile-Cys-Ala-Thr-Gly-Leu-OH ) 目录号 : GP10142Deubiquitinates uH2A/uH2B
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
The ubiquitin specific protease 3 USP3 is a deubiquitinating enzyme for uH2A and uH2B. USP3 dynamically associates with chromatin and deubiquitinates H2A/H2B in vivo. The ZnF-UBP domain of USP3 mediates uH2AUSP3 interaction. Functional ablation of USP3 by RNAi leads to delay of S phase progression and to accumulation of DNA breaks, with ensuing activation of DNA damage checkpoint pathways. In response to ionizing radiation, (1) uH2A redistributes and colocalizes in g-H2AX DNA repair foci and (2) USP3 is required for full deubiquitination of ubiquitin-conjugates/uH2A and g-H2AX dephosphorylation. USP3 is a novel regulator of H2A and H2B ubiquitination, highlight its role in preventing replication stress, and suggest its involvement in the response to DNA double-strand breaks1.
USP3 has been characterized as a functional DUB in vitro, and it is the human DUB most homologous to S. cerevisiae Ubp8, which regulates H2B deubiquitination2-4.
References:
1.F. Nicassio, N. Corrado et al. Human USP3 Is a Chromatin Modifier Required for S Phase Progression and Genome Stability. Current Biology 17, 1972–1977.
2.Sloper-Mould, K.E., Eyre, H.J., Wang, X.W., Sutherland, G.R., and Baker, R.T. (1999). Characterization and chromosomal localization of USP3, a novel human ubiquitin-specific protease. J. Biol. Chem. 274, 26878–26884.
3.Henry, K.W., Wyce, A., Lo, W.S., Duggan, L.J., Emre, N.C., Kao, C.F., Pillus, L., Shilatifard, A., Osley, M.A., and Berger, S.L. (2003). Transcriptional activation via sequential histone H2B ubiquitylation and deubiquitylation, mediated by SAGA-associated Ubp8. Genes Dev. 17, 2648–2663.
4.Zhang, Y. (2003). Transcriptional regulation by histone ubiquitination and deubiquitination. Genes Dev. 17, 2733–2740.
Cas No. | SDF | ||
别名 | H2N-Ser-Thr-Thr-Ala-Ile-Cys-Ala-Thr-Gly-Leu-OH | ||
Canonical SMILES | NC(CO)C(NC(C(O)C)C(NC(C(C)O)C(NC(C)C(NC(C(C)CC)C(NC(CS)C(NC(C)C(NC(C(O)C)C(NCC(NC(CC(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O | ||
分子式 | C38H68N10O15S | 分子量 | 937.07 |
溶解度 | ≥ 93.7mg/mL in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.0672 mL | 5.3358 mL | 10.6716 mL |
5 mM | 0.2134 mL | 1.0672 mL | 2.1343 mL |
10 mM | 0.1067 mL | 0.5336 mL | 1.0672 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。